CH Innovations

magAssist, founded in 2017 by Dr. Xu Bozhen, is a high-tech enterprise based in Suzhou, specializing in the development of in-vitro artificial heart devices aimed at assisting patients with cardiovascular diseases. The company focuses on creating short-term to medium-term ventricular assist devices that are compatible with various blood types. Utilizing advanced fluid mechanics and magnetic suspension technology, magAssist aims to minimize incompatibility issues in patients, thereby enhancing their recovery and treatment processes. The core team consists of leading experts in artificial heart engineering, leveraging extensive experience in research and development to produce domestically manufactured devices with independent intellectual property rights.

Founded in 2014, Aldatu Biosciences specializes in adaptive PCR diagnostics for global health. Its proprietary PANDAA technology enables detection of highly variable genomic regions, empowering healthcare providers to improve patient outcomes and reduce costs, particularly in HIV care.

Noninvasix, Inc., established in 2007, is a medical technology company based in Galveston, Texas. It develops non-invasive precision oximetry systems designed to measure oxygen sufficiency within organs and veins without the need for invasive catheters. The company's primary focus is on monitoring brain oxygenation in preterm babies within newborn intensive care units (NICUs). Noninvasix has raised over $6.8 million in funding, including a seed round in late 2021, and has been supported by grants from the NIH and DOD totaling $6 million. The company's technology has been clinically validated and is protected by a robust IP portfolio comprising 9 U.S. and 8 global patents. Noninvasix has participated in prestigious accelerator programs such as Philips Healthworks and TMCx, and its innovations have earned multiple awards.